A reevaluation of integrins as regulators of angiogenesis.
Pharmacological agents directed against the integrins alpha(v)beta(3) and alpha(v)beta(5) have been reported to inhibit angiogenesis. However, genetic ablations of the genes encoding these integrins fail to block angiogenesis and in some cases even enhance it. This apparent paradox suggests the hypotheses that these integrins are negative regulators of angiogenesis and that the drugs targeting them may be acting as agonists rather than antagonists.
Howard Hughes Medical Institute and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. rohynes@mit.edu
Richard O
RO
Hynes
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis / Q000502:physiology; D001324:Autoantigens / Q000494:pharmacology; D024141:Collagen Type IV / Q000494:pharmacology; D006801:Humans; D016023:Integrins / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D019030:Receptors, Vitronectin / Q000187:drug effects / Q000235:genetics / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001324:Autoantigens; D024141:Collagen Type IV; D016023:Integrins; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5; C057112:type IV collagen alpha3 chain; C112567:etaracizumab